S. 476 · 118th Congress

Maintaining Investments in New Innovation Act

Introduced on Feb 16, 2023 by Robert Menendez (D-NJ). 3 cosponsors, 3 of them from another party. Latest action (Feb 16, 2023): Read twice and referred to the Committee on Finance.

Stage
Introduced
Introduced
Feb 16, 2023
Cosponsors
3
3 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Subjects

  • Genetics
  • Medicare
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Robert MenendezD-NJSponsor

Republicans · 3

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 16, 2023Introduced in Senate
  2. Feb 16, 2023 · SenateRead twice and referred to the Committee on Finance.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ALNYLAM PHARMACEUTICALS, INC.19 reports
    $220K reported (all issues)
  2. NOVARTIS CORPORATION19 reports
    $6.9M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  3. GENENTECH INC.5 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  4. INTERNATIONAL BROTHERHOOD OF TEAMSTERS5 reports
    $1.4M reported (all issues)
  5. IONIS PHARMACEUTICALS, INC.5 reports
    $160K reported (all issues)
  6. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA4 reports
    $6.4M reported (all issues)
  7. ALEXION PHARMACEUTICALS INC.3 reports
    $240K reported (all issues)Federal contractor: ALEXION PHARMACEUTICALS INC$733.6K in contracts, FY2026AI match · 99%
  8. BIOTECHNOLOGY INNOVATION ORGANIZATION3 reports
    $5.3M reported (all issues)
  9. GILEAD SCIENCES, INC.3 reports
    Federal contractor: GILEAD SCIENCES INCAI match · 100%
  10. Ionis Pharmaceutical, Inc.3 reports
    $90K reported (all issues)
  11. AARP2 reports
    $10M reported (all issues)
  12. Personalized Medicine Coalition2 reports
    $85K reported (all issues)
  13. ACADIA PHARMACEUTICALS1 report
    $510K reported (all issues)
  14. GSK (fka GLAXOSMITHKLINE INC.)1 report
    $1.5M reported (all issues)
  15. Healthcare Leadership Council1 report
    $110K reported (all issues)
  16. MERCK & CO., INC.1 report
    $1.9M reported (all issues)Federal contractor: MERCK SHARP & DOHME LLC$445.3K in contracts, FY2026AI match · 100%
  17. Vir Biotechnology, Inc.1 report
    $70K reported (all issues)Federal contractor: VIR BIOTECHNOLOGY, INC.AI match · 100%

Reports filed in 2023, 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.